Objective responses can be obtained by CTLA-4 inhibition in metastatic melanoma after BRAF inhibitor failure

Melanoma Research

Volumn 25, Issue 1, 2015, Pages 68-74

  Schreuer, Max S ^a   Chevolet, Ines L ^c   Jansen, Yanina J ^a   Seremet, Teofila C ^a   Wilgenhof, Sofie ^a   Liénard, Danielle ^b   Del Marmol, Veronique ^b   Neyns, Bart ^a  

^a UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

^b ERASME HOSPITAL   (Belgium)

^c GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

BRAF inhibitor; ipilimumab; melanoma; sequential treatment

Indexed keywords

AUTOLOGOUS MICRORNA ELECTROPORATED DENDRITIC CELL VACCINE; B RAF KINASE INHIBITOR; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DABRAFENIB; DENDRITIC CELL VACCINE; IPILIMUMAB; UNCLASSIFIED DRUG; VEMURAFENIB; B RAF KINASE; BIOLOGICAL MARKER; BRAF PROTEIN, HUMAN; CANCER VACCINE; CTLA4 PROTEIN, HUMAN; MESSENGER RNA; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CLINICAL ARTICLE; COHORT ANALYSIS; DISEASE SEVERITY; DRUG TREATMENT FAILURE; ENZYME INHIBITION; FEMALE; HUMAN; MAINTENANCE THERAPY; METASTATIC MELANOMA; MONOTHERAPY; OVERALL SURVIVAL; RETROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; ANTAGONISTS AND INHIBITORS; DISEASE COURSE; ELECTROPORATION; IMMUNOTHERAPY; MELANOMA; METABOLISM; METASTASIS; PREDICTIVE VALUE; PROCEDURES; SKIN NEOPLASMS;

ANTIBODIES, MONOCLONAL; BIOLOGICAL MARKERS; CANCER VACCINES; CTLA-4 ANTIGEN; DISEASE PROGRESSION; ELECTROPORATION; HUMANS; IMMUNOTHERAPY; MELANOMA; NEOPLASM METASTASIS; PREDICTIVE VALUE OF TESTS; PROTO-ONCOGENE PROTEINS B-RAF; RETROSPECTIVE STUDIES; RNA, MESSENGER; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 84920277771     PISSN: 09608931     EISSN: 14735636     Source Type: Journal    
DOI: 10.1097/CMR.0000000000000131     Document Type: Article

References (27)

1. Sharma A, Tran MA, Liang S, Sharma AK, Amin S, Smith CD, et al. Targeting mitogen-activated protein kinase/extracellular signal-regulated kinase kinase in the mutant (V600E) B-Raf signaling cascade effectively inhibits melanoma lung metastases. Cancer Res 2006; 66:8200-8209.
2. Gray-Schopfer V, Wellbrock C, Marais R. Melanoma biology and new targeted therapy. Nature 2007; 445:851-857.
3. Hodis E, Watson IR, Kryukov GV, Arold ST, Imielinski M, Theurillat JP, et al. A landscape of driver mutations in melanoma. Cell 2012; 150:251-263.
4. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. BRIM-3 Study Group. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364:2507-2516.
5. Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 2012; 380:358-365.
6. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711-723.
7. Robert C, Thomas L, Bondarenko I, O'Day S, Weber J, Garbe C, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364:2517-2526.
8. Wolchok JD, Neyns B, Linette G, Negrier S, Lutzky J, Thomas L, et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol 2010; 11:155-164.
9. Shahabi V, Whitney G, Hamid O, Schmidt H, Chasalow SD, Alaparthy S, Jackson JR. Assessment of association between BRAF-V600E mutation status in melanomas and clinical response to ipilimumab. Cancer Immunol Immunother 2012; 61:733-737.
10. Prieto PA, Yang JC, Sherry RM, Hughes MS, Kammula US, White DE, et al. CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma. Clin Cancer Res 2012; 18:2039-2047.
11. Hodi FS. Advanced melanoma: pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in metastatic or locally advanced, unresectable melanoma. European Cancer Congress, 2013 [abstract no: LBA 24].
12. Wilgenhof S, Du Four S, Vandenbroucke F, Everaert H, Salmon I, Liénard D, et al. Single-center experience with ipilimumab in an expanded access program for patients with pretreated advanced melanoma. J Immunother 2013; 36:215-222.
13. Ribas A, Kefford R, Marshall MA, Punt CJ, Haanen JB, Marmol M, et al. Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol 2013; 31:616-622.
14. Ribas A, Hodi FS, Callahan M, Konto C, Wolchok J. Hepatotoxicity with combination of vemurafenib and ipilimumab. N Engl J Med 2013; 368:1365-1366.
15. Puzanov ICM, Linette PG, Patel SP, Luke JJ, Sosman JA, et al. Phase 1 study of the BRAF inhibitor dabrafenib with or without the MEK inhibitor trametinib in combination with ipilimumab for V600E/K mutation-positive unresectable or metastatic melanoma [abstract 2511]. J Clin Oncol 2014; 32:5s.
16. Ascierto PA, Simeone E, Sileni VC, Del Vecchio M, Marchetti P, Cappellini GC, et al. Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: data from the Italian cohort of the ipilimumab expanded access program. Cancer Invest 2014; 32:144-149.
17. Ackerman A, Klein O, McDermott DF, Wang W, Ibrahim N, Lawrence DP, et al. Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors. Cancer 2014; 120:1695-1701.
18. Neyns B, Wilgenhof S, Corthals J, Heirman C, Thielemans C. Phase II study of autologous mRNA electroporated dendritic cells (TriMixDC-MEL) in combination with ipilimumab in patients with pretreated advanced melanoma [abstract 3014]. J Clin Oncol 2014; 32:5s.
19. Benteyn D, Van Nuffel AM, Wilgenhof S, Bonehill A. Single-step antigen loading and maturation of dendritic cells through mRNA electroporation of a tumor-associated antigen and a TriMix of costimulatory molecules. Method Mol Biol 2014; 1139:3-15.
20. Wolchok JD, Hoos A, O'Day S, Weber JS, Hamid O, Lebbé C, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 2009; 15:7412-7420.
21. Hu-Lieskovan S, Robert L, Homet Moreno B, Ribas A. Combining targeted therapy with immunotherapy in BRAF-mutant melanoma: promise and challenges. J Clin Oncol 2014; 32:2248-2254.
22. Cartlidge RA, Thomas GR, Cagnol S, Jong KA, Molton SA, Finch AJ, McMahon M. Oncogenic BRAF(V600E) inhibits BIM expression to promote melanoma cell survival. Pigment Cell Melanoma Res 2008; 21:534-544.
23. Boni A, Cogdill AP, Dang P, Udayakumar D, Njauw CN, Sloss CM, et al. Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Res 2010; 70:5213-5219.
24. Wilmott JS, Long GV, Howle JR, Haydu LE, Sharma RN, Thompson JF, et al. Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma. Clin Cancer Res 2012; 18:1386-1394.
25. Frederick DT, Piris A, Cogdill AP, Cooper ZA, Lezcano C, Ferrone CR, et al. BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin Cancer Res 2013; 19:1225-1231.
26. Diaz LA Jr, Bardelli A. Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol 2014; 32:579-586.
27. Diehl F, Schmidt K, Choti MA, Romans K, Goodman S, Li M, et al. Circulating mutant DNA to assess tumor dynamics. Nat Med 2008; 14:985-990.